Inhaled triamcinolone acetonide HFA 450 μg twice daily compared with beclomethasone dipropionate CFC 500 μg twice daily in adults with moderate persistent asthma

Clinical Drug Investigation

Volumn 20, Issue 1, 2000, Pages 9-17

  Bateman, Eric D ^a   Adler, Lawrence ^b   Chyrek Borowska, Sabina ^c   Theman, Kaj ^d   Rogeaux, Yves ^e   Schultze Werninghaus, Gerhard ^f   Nel, Annalene M ^g   Pasquet, Jean Paul ^h   Notelet, Dominique ^h   Hardy, Pierre ^h   Petillo, John ^h   Banerji, Donald ^h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Belmont Health Centre   (United Kingdom)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d Lung o Allergiklin   (Sweden)

^e Assoc d'Etudes en Pneumologie L   (France)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g Clinical Trial Centre   (South Africa)

^h SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; FLUORINATED HYDROCARBON; SALBUTAMOL; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; INHALER; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033909897     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020010-00002     Document Type: Article

References (26)

1. 1. British Asthma Guidelines on Asthma Management: 1995 Review and Position Statement. Thorax 1997; 52: S1-S21
2. 2. Global initiative for asthma - global strategy for asthma management and prevention. National Heart, Lung, and Blood Institute/World Health Organization Workshop. 1995; Pub no. 95-3659
3. 3. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26
4. 4. Barnes PJ, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1-53
5. 5. Boushey HA. Effects of inhaled corticosteroids on the consequences of asthma. J Allergy Clin Immunol 1998; 102: S5-S16
6. 6. Welch MJ, Levy S, Smith JA, et al. Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 1997; 112: 597-606
7. 7. Bernstein DI, Cohen R, Ginchansky E, et al. A multicenter, placebo-controlled study of twice-daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. J Allergy Clin Immunol 1998; 101: 433-8
8. 8. Ramsdell JW, Fish L, Graft D, et al. A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1998; 80: 385-90
9. 9. United States Pharmacopeial Convention. Dosage unit sampling for metered-dose inhalers. Pharmacopeial Forum 1998; 24: 6940-2
10. 10. Dockhorn R, Vanden Burgt JA, Ekholm BP, et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995; 96: 50-6
11. 11. Alexander DJ. Safety of propellants. J Aerosol Med 1995; 8 Suppl. 1: S42-7
12. 12. Heald DL, Berridge M, Lee Z, et al. Lung deposition of triamcinolone acetonide with and without the integrated spacer as determined by positron emission tomography and spiral CT. J Allergy Clin Immunol 1998; 101 (1 Pt 2): S9-38
13. 13. Welch M, Bernstein D, Gross G, et al. A controlled trial of chloroflurocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Chest 1999; 116: 1304-12
14. 14. Jacobson K, Chervinsky P, Noonan M, et al. Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-cfc propellant hfa 134a in patients with asthma. Ann Allergy Asthma Immunol 1999; 83:327-33
15. 15. Nelson HS, Kane RE, Petillo J, et al. Long-term safety of a non-CFC-containing triamcinolone acetonide inhalation aerosol in patients with asthma. J Asthma 2000; 37: 145-52
16. 16. Pearlman DS, Kane RE, Banerji D, et al. Comparative dose-ranging study of triamcinolone acetonide inhalation aerosol using propellants HFA-134a or P-12 in children with asthma, Current Therapeutic Research 1999; 60: 595-606
17. 17. Fuller Hallett C, Dahl R. Assessing equivalence of inhaled drugs. Respir Med 1995; 89: 525-7
18. 18. Zanen P, Lammers JW. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995; 48: 179-84
19. 19. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-75
20. 20. Chrystn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet 1994; 26: 1-6
21. 21. Deron E, Pauwels R. Bioequivalence of inhaled drugs. Eur Resp J 1995; 8: 1634-6
22. 22. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-9
23. 23. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94: 676-83
24. 24. Busse W. Dose-related efficacy of Pulmicort® (budesonide) Turbohaler® in moderate to severe asthma. J Allergy Clin Immunol 1994; 94: 186
25. 25. Bronsky E, Korenblat P, Harris AG, et al. Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma. Ann Allergy Asthma Immunol 1998; 80: 295-302
26. 26. Berkowitz R, Rachelefsky G, Harris AG, et al. A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics. Chest 1998; 114: 757-65